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Abstract
Relapse to alcohol use after periods of abstinence is a hallmark behavioral pathology of alcoholism
and a major clinical problem. Emerging evidence indicates that metabotropic glutamate receptor 5
(mGluR5) antagonists attenuate relapse to alcohol-seeking behavior but the molecular mechanisms
of this potential therapeutic effect remain unexplored. The extracellular signal-regulated kinase
(ERK1/2) pathway is downstream of mGluR5 and has been implicated in addiction. We sought to
determine if cue-induced reinstatement of alcohol-seeking behavior, and its reduction by an mGluR5
antagonist, is associated with changes in ERK1/2 activation in reward-related limbic brain regions.
Selectively bred alcohol-preferring (P) rats were trained to lever press on a concurrent schedule of
alcohol (15% v/v) vs. water reinforcement. Following 9 days of extinction, rats were given an
additional extinction trial or injected with the mGluR5 antagonist MPEP (0, 1, 3, or 10 mg/kg) and
tested for cue-induced reinstatement. Brains were removed 90-min later from the rats in the extinction
and MPEP (0 or 10 mg/kg) conditions for analysis of p-ERK1/2, total ERK1/2, and p-ERK5
immunoreactivity (IR). Cue-induced reinstatement of alcohol-seeking behavior was associated with
a 3–5 fold increase in p-ERK1/2 IR in the basolateral amygdala and nucleus accumbens shell. MPEP
administration blocked both the relapse-like behavior and increase in p-ERK1/2 IR. P-ERK1/2 IR in
the central amygdala and NAcb core was dissociated with the relapse-like behavior and the
pharmacological effect of mGluR5 blockade. No changes in total ERK or p-ERK5 were observed.
These results suggest that exposure to cues previously associated with alcohol self-administration is
sufficient to produce concomitant increases in relapse-like behavior and ERK1/2 activation in specific
limbic brain regions. Pharmacological compounds, such as mGluR5 antagonists, that reduce cue-
induced ERK1/2 activation may be useful for treatment of relapse in alcoholics that is triggered by
exposure to environmental events.
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INTRODUCTION
Alcoholism is a complex neuropsychiatric disorder that is characterized by recurring cycles of
chronic drinking, abstinence and relapse. Emerging evidence suggests that alcohol and other
drugs of abuse may produce maladaptive changes in a variety of molecular and cell signaling
pathways that lead to enduring changes in brain structure and function (Crews et al., 1996;
Fadda and Rossetti, 1998; Nestler and Aghajanian, 1997). These neuroadaptations are thought
to regulate the progressive and recurring behavioral pathologies that occur in alcoholism
(Breese et al., 2005; Pandey et al., 2003; Ron and Jurd, 2005). Understanding drug-induced
plasticity in brain and behavioral functions is of potential importance for development of new
pharmacotherapies for problems associated with alcoholism, such as relapse (Anton et al.,
1995; Heinz et al., 2003; Mann, 2004).
A growing number of studies have shown that metabotropic glutamate receptor 5 (mGluR5)
activity regulates alcohol-related behavioral processes in animal models. For example, the
mGluR5 antagonist 2-Methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP) inhibits the
reinforcing (Cowen et al., 2005; Hodge et al., 2006; Schroeder et al., 2005) and discriminative
stimulus effects of investigator- (Besheer and Hodge, 2005) and self-administered (Besheer et
al., 2006) alcohol in rodents. Similarly, pharmacological blockade of mGluR5 prevents relapse-
like behavior as measured by cue-induced reinstatement (Backstrom et al., 2004) and alcohol
deprivation procedures (Schroeder et al., 2005). Although these findings indicate mGluR5
blockade attenuates relapse to alcohol-seeking behavior, the molecular or cell signaling
mechanisms associated with this potential therapeutic effect remain unexplored.
Extracellular signal-regulated kinase (ERK) is one potential downstream mediator of mGluR5
activity (Yang et al., 2004) that is also known to modulate adaptive processes such as learning,
memory, and synaptic plasticity (Sweatt, 2004; Thomas and Huganir, 2004) as well as
maladaptive forms of plasticity associated with drug use (Girault et al., 2007; Valjent et al.,
2006). The two closely related isoforms of ERK (ERK1 and ERK2, or ERK1/2) are activated
by dual phosphorylation on both a threonine and tyrosine residue by MEK1/2 (Anderson et al.,
1990); reviewed by (Cobb, 1999). Activated ERK1/2 phosphorylates cellular targets or
translocates to the nucleus where it activates specific gene transcription factors (Grewal et al.,
1999). By regulating cellular activities and gene transcription, the ERK1/2 cascade transduces
the activity of a variety of extracellular and intracellular signals into enduring changes in CNS
structure and function (Pearson et al., 2001; Qi and Elion, 2005; Treisman, 1996; Valjent et
al., 2000; Valjent et al., 2006).
Alcohol exposure produces changes in the active (i.e., phosphorylated) form of ERK1/2 (p-
ERK1/2) in brain regions that are of significance to behavioral pathologies associated with
addiction (Chandler and Sutton, 2005; Davis et al., 1999; Kalluri and Ticku, 2002a; Sanna et
al., 2002; Tsuji et al., 2003). For example, acute ethanol has been shown to produce a dose-
and time-dependent decrease in p-ERK1/2 levels in mouse and rat cerebral cortex (Chandler
and Sutton, 2005; Kalluri and Ticku, 2002b; Tsuji et al., 2003); but other studies have shown
that acute ethanol increases ERK1/2 phosphorylation in the Edinger-Westphal nucleus
(Bachtell et al., 2002) and amygdala (Pandey et al., 2008). Forced exposure to chronic ethanol
and withdrawal alter ERK1/2 phosphorylation in brain regions that regulate alcohol self-
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administration and relapse-like behavior, including the amygdala (Pandey et al., 2008; Sanna
et al., 2002).
Although the mechanisms by which alcohol alters ERK1/2 phosphorylation are not fully
characterized, converging evidence indicates that mGluR5 may regulate both ERK1/2
activation and the neural effects of alcohol. For example, pharmacological activation of Group
I metabotropic glutamate receptors (mGluR1 and mGluR5), via site-specific infusion of the
agonist DHPG, increases ERK1/2 phosphorylation in rat striatum (Choe and Wang, 2001). This
effect of the nonselective agonist is fully blocked by the mGluR5 antagonist MPEP in cultured
striatal neurons but not altered by an mGluR1 antagonist (Yang et al., 2004), which suggests
mGluR5 specificity in ERK1/2 activation. Other data show that ethanol inhibits mGluR5
activity in vitro (Minami et al., 1998), which could lead to reduced ERK1/2 activation as noted
above. When taken together with evidence that cue-induced reinstatement of alcohol-seeking
behavior has recently been linked to increase ERK1/2 phosphorylation in the amygdala
(Radwanska et al., 2008), these findings suggest that mGluR5 antagonist-induced effects on
relapse-like behavior may be associated inhibition of ERK1/2 activation in specific brain
regions.
To address this hypothesis, the present study was designed to first determine if the mGluR5
antagonist MPEP would inhibit cue-induced reinstatement of alcohol-seeking behavior in
selectively-bred alcohol-preferring (P) rats (Li et al., 1979). Second, we examined p-ERK1/2
immunoreactivity (IR) in the nucleus accumbens and amygdala following extinction,
reinstatement, and MPEP treatment to determine if the behavioral effects of MPEP are
associated with altered ERK 1/2 activation. These brain regions were chosen for study because
they are key elements in the neurobiological regulation of associative learning processes in
drug addiction and reward (Everitt et al., 1999), are known to mediate the reinforcing and
subjective effects of alcohol (Besheer et al., 2003; Hodge et al., 1995; Hodge and Cox, 1998;
Schroeder et al., 2003), and have recently been linked to alcohol relapse-like behavior in
rodents (Dayas et al., 2007; Zhao et al., 2006) and cue-induced craving in abstinent human
alcoholics (Schneider et al., 2001). Third, we examined total ERK1/2 IR to establish if changes
in p-ERK1/2 IR were associated with altered abundance of the kinase. Finally, adjacent brain
sections were processed for p-ERK5 IR in an effort to address potential specificity of




Male alcohol-preferring (P) rats (N=31 total) were bred from a line provided by Indiana
University (courtesy of Dr. T.K. Li) and housed two per cage in Plexiglas cages. This rat strain
was chosen for study because it has been found to fulfill the requirements of an animal model
of alcoholism (Cicero, 1979; Lester and Freed, 1973), including voluntarily consumption of
alcohol in quantities that produce significant blood alcohol concentrations (50–200 mg%), self-
administration of alcohol for its pharmacological rather than the sensory effects and
development of tolerance and dependence through voluntary drinking (Kampov-Polevoy et
al., 2000; Li et al., 1987; Murphy et al., 2002). The animal colony room was maintained on a
12L: 12D cycle with the lights on at 07:00. All experimental procedures were conducted under
institutional and NIH guidelines.
Self-Administration Apparatus
Self-administration, extinction, and reinstatement sessions were conducted in Plexiglas operant
chambers for rats (Med Associates, Georgia, VT). Each chamber was housed in a sound-
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attenuating cubicle equipped with a fan that provided ventilation and helped to mask external
noise. The left and right wall of each operant chamber was equipped with one ultra-sensitive
stainless steel response lever, a cue-light, and a liquid delivery system. Liquid solutions
(ethanol or water) were maintained in 60 ml syringes mounted on a programmable pump
(PHM-100, Med Associates), which delivered 0.1 ml per activation into a stainless steel cup
located to the left of the associated response lever. Head entries into the drinking cup were
recorded when an infrared photo beam was broken. Each chamber also contained a house light.
The chambers were interfaced (Med Associates) to an IBM-PC compatible computer.
Self-Administration, Extinction, and Reinstatement Procedure
After 2 weeks of adaptation to laboratory housing conditions, fluid access was restricted to 1-
h per day (for 2 days only) and the rats were trained to lever press by reinforcement of successive
approximations with sucrose (10% w/v) vs. water available as reinforcers on a concurrent fixed
ratio-1 (CONC FR1-FR1) schedule of reinforcement during two 16-h overnight sessions. Daily
(M-F) 30-min sessions were conducted with sucrose (10% w/v) vs. water available
concurrently. When sucrose and water responding stabilized (i.e., <10% daily variation for 5
days), the rats were trained to self-administer concurrent ethanol (15% v/v) vs. water using a
sucrose fading procedure (Samson, 1986) as previously described (Hodge et al., 1993). Briefly,
ethanol was added to the sucrose solution over a 4-week period and then the sucrose was faded
out of the solution until P-rats were self-administering 15% ethanol vs. water. During operant
training sessions, responses on the ethanol-paired lever resulted in the presentation of a
compound stimulus consisting of a visual cue light and the auditory stimulus of pump activation
from a fixed spatial location. Responses on the water-paired lever resulted in the presentation
of a similar compound stimulus, but from an alternate fixed spatial location.
Following a 1-month period of baseline responding, operant responding was extinguished by
removing all consequences of lever responding (i.e., cue-light, pump sound, and ethanol or
water delivery). Following 9 sequential days of extinction training, P-rats responded upon the
formerly alcohol and water paired levers equivalently, indicating an extinction of selective
responding on the alcohol-paired lever. On day 10, the P-rats were given a reinstatement test
in which lever press responses were followed by presentation of the cue light and auditory cue
(as during training) in the absence of ethanol or water reinforcement to examine cue-induced
ethanol-seeking behavior. One hour prior to the reinstatement session 4 separate groups of P-
rats were injected with the mGluR5 antagonist MPEP (0, 1, 3 or 10 mg/kg) to determine if
MPEP alters cue-induced reinstatement of alcohol-seeking behavior in this genetic model of
alcoholism. Each drug dose group consisted of n=6 rats with the exception of the MPEP (1
mg/kg) group, which was n=7 rats. A fifth group of P-rats (n=6) was given another day of
extinction training to serve as a control for the reinstatement conditions. Groups were matched
on body weight, baseline response totals, and extinction performance prior to drug testing.
Drugs
Ethanol solutions were prepared by mixing appropriate volumes of ethanol (95% v/v) and
distilled water. Sucrose (w/v) solutions consisted of granulated cane sugar dissolved in distilled
water. Ethanol, sucrose, and water solutions were presented at room temperature. MPEP
(Tocris Bioscience, Ellisville, Missouri) was dissolved in physiological saline and injected in
a volume of 1 ml/kg body weight.
Immunohistochemistry
Ninety minutes after the reinstatement test session, rats were deeply anesthetized with
pentobarbital (100 mg/kg IP) and transcardially perfused with ice cold 0.1 M phosphate
buffered saline (PBS; pH 7.4) followed by 4% paraformaldehyde. The intact skulls were
postfixed overnight, and then rinsed with PBS. Brains were removed from the skull and stored
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in PBS at 4°C. Coronal vibratome sections (40 µm) were collected and stored (−20°C) in
cryoprotectant until immunohistochemistry processing. Endogenous peroxidase was blocked
by incubating the free floating sections for 10 min in 0.6% H2O2 followed by citra buffer
antigen retrieval performed at 70°C for 30 min (Antigen Retrieval Citra, BioGenex, San
Ramon, CA). Sections were blocked in PBS/0.1%triton-x/4% horse serum for 30 minutes and
incubated at +4°C overnight in primary polyclonal antibody to p-ERK1/2 (1:400), ERK1/2
(1:500), or p-ERK5 (1:1000) from Cell Signaling Technology (Danvers, MA). The sections
were then incubated in secondary antibody for one hour using the Dako EnVision Kit (Dako,
Carpinteria, CA). Immunoreactivity was detected with nickel-enhanced diaminobenzidine
(Dako EnVision Kit) as a chromagen. Sections were then counterstained with toluidine blue,
mounted, dried and coverslipped with Cytoseal. For consistency of staining across subjects,
brain tissue from all groups was processed simultaneously.
Immunoreactivity was visualized using an Olympus CX41 light microscope (Olympus
America, Center Valley, PA). Images were acquired using a digital camera (Regita model,
QImaging, Burnaby, BC) interfaced to a desktop computer (Dell, Round Rock, TX). Image
analysis software (Bioquant Nova Advanced Image Analysis; R&M Biometric, Nashville, TN)
was used to quantify immunoreactivity. The microscope, camera, and software were
background corrected and normalized to preset light levels to ensure fidelity of data acquisition.
Pixel density and cell count measurements were calculated from a circumscribed field (e.g.,
brain region) and divided by the area of the region and expressed as pixels/mm2.
Immunoreactivity data were collected by a researcher blind to treatment conditions. Data for
p-ERK1/2 IR data were acquired from a minimum of 4 sections/brain region/animal and
averaged to obtain a single value per subject. Total ERK1/2 and p-ERK5 IR were evaluated in
a single section adjacent to those used for p-ERK1/2 from each animal. The brain regions
examined were the nucleus accumbens (core and shell; AP +1.7 to 1.0 mm; see Figure 2B) and
the amygdala (basolateral and central nucleus; AP −2.8 to 3.3 mm; see Figure 2C).
Data Analysis
The principal behavioral parameters of operant ethanol self-administration analyzed were
number of ethanol and water lever presses, volume of ethanol consumed (mls), and response
latency (i.e., temporal delay to the first ethanol response). Ethanol intake (g/kg) was determined
using each animal’s daily body weight and the volume of ethanol delivered per reinforcer (0.1
ml of 15% v/v ethanol). Extinction data were analyzed statistically by two-way repeated
measures analysis of variance (RM ANOVA) with factors for lever (ethanol vs. water) and
day. MPEP dose effects on reinstatement were analyzed by two-way RM ANOVA with factors
for drug dose (between subjects) and response lever (within subject). Immunohistochemistry
data were analyzed statistically by one-way ANOVA. Significant main effects and interactions
were followed by post hoc multiple comparisons (Tukey test) test using SigmaStat v. 3.0 (Systat
Software, La Jolla, CA)
RESULTS
Baseline Performance
On the last day of baseline P-rats from all treatment groups combined (N=31 total) responded
significantly more on the ethanol lever as compared to the concurrently available water lever
(F(1,30)=66.8, p<0.0001) (Figure 1A, left). This resulted in an average ethanol dose of 0.81 ±
0.06 g/kg/30-min with a strong preference for ethanol over water of 87.5%, which is typical
for this genetically selected rat line (Besheer et al., 2008; Schroeder et al., 2005). A two-way
ANOVA (Reinforcer X Treatment Condition) conducted on data from the last day of baseline
showed that there were no differences in total ethanol and water reinforced responding among
the groups of rats that went on to receive extinction only or extinction followed by MPEP (0,
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1, 3, or 10 mg/kg, IP) administration prior to cue-induced reinstatement (F (4, 52)=0.32, p =
0.86, ns). Thus, any subsequent differences seen on reinstatement tests were not likely related
to differential baseline performance.
Extinction of Alcohol Self-Administration
During the nine days of extinction, rats from all treatment groups (N=31 total) emitted
significantly more responses on the lever that previously produced ethanol reinforcement (F
(1,30) = 155, p < 0.001) (Figure 1A, right). Although responding on both ethanol and water
levers decreased as a function of time (F(8,240) = 58, p <0.001), the magnitude of change was
greater for responses on the ethanol lever as indicated by the significant statistical interaction
between reinforcement condition (ethanol × water) and time (F(8,240) = 44.5, p < 0.001).
Multiple comparison procedures (Tukey test) showed that responses on the ethanol-associated
lever decreased as a function of time and were not different from water responding on the last
two days (8 and 9) of extinction (Figure 1B, right). Additional analysis of extinction
performance using separate two-way ANOVAs showed that there were no differences in total
ethanol (F(4,208) = 0.32, ns) or water (F(4,208) = 0.67, p = 0.62, ns) lever responses during
the nine days of extinction between the five treatment groups that went on to receive
EXTINCTION or EXTINCTION followed by MPEP (0, 1, 3, or 10 mg/kg). These data show
extinction of ethanol reinforced responding (i.e., equivalent responding on levers that
previously produced ethanol and water reinforcement) in alcohol preferring P-rats when all
consequences of lever pressing were removed for 9 days. In addition, subsequent group
differences on reinstatement tests were not a function of differential between-group rates of
extinction.
Cue-induced Reinstatement of Alcohol-Seeking Behavior: Blockade by MPEP
On day 10 of the procedure, one group of rats was administered a saline pretreatment injection
and continued under the extinction condition. The other four groups of rats were pretreated
with MPEP (0, 1, 3, or 10 mg/kg) and underwent reinstatement tests in which responses on
either the ethanol- or water-associated lever resulted in presentation of discrete cues (stimulus
light above the lever and pump sound) that were previously paired with reinforcer delivery
during baseline. Overall, the behavioral data demonstrate cue-induced reinstatement of
alcohol-seeking behavior that was blocked by the mGluR5 antagonist MPEP (Figure 1B).
Statistical analysis using a two-way repeated measures ANOVA with one factor repetition
revealed a significant main effect of reinforcement condition (F (1, 4) = 34.7), p < 0.001) due
to an overall increase in responding on the ethanol-associated lever across the 5 treatment
conditions (Figure 1B). There was also a significant main effect of treatment condition (F (4,
26) = 4.9, p = 0.004) and interaction between treatment and reinforcement conditions (F (4,
26) = 4.4, p = 0.007), which indicates that the increases in responding on the ethanol lever were
dependent on the treatment condition (i.e., Extinction or MPEP dose). Multiple comparison
procedures (Tukey test) comparing extinction performance to MPEP (0 mg/kg) showed
significant cue-induced reinstatement of ethanol-seeking behavior with no change in
responding on the concurrently available water lever (Figure 1B). Moreover, MPEP (1 and 10
mg/kg) selectively blocked cue-induced reinstatement of ethanol-seeking behavior with no
significant suppression of water responding (Figure 1B). However, the effect of the middle
dose of MPEP (3 mg/kg) did not reach statistical significance due to variability in performance
of one rat that responded on the ethanol-associated lever at a rate that was 3 standard errors
above the group mean. Otherwise, the response totals following MPEP (3 mg/kg) were
indistinguishable from those following the low dose.
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Nucleus Accumbens (shell and core)—Cue-induced reinstatement of alcohol-seeking
behavior and its blockade by MPEP (10 mg/kg) was associated with an overall significant
change in p-ERK1/2 IR in the shell of the nucleus accumbens (F (2, 15) = 45.5, p < 0.0001).
Multiple comparison procedures showed that cue-induced reinstatement of alcohol-seeking
was associated with a 5-fold increase in p-ERK1/2 IR as compared to the extinction condition
(Tukey, p<0.05; Figure 2A). Administration of a dose of the mGluR5 antagonist MPEP (10
mg/kg) that blocked cue-induced reinstatement of alcohol-seeking behavior also completely
blocked the increase in p-ERK1/2 IR that occurred following saline administration (Tukey,
p<0.05; Figure 2A). Additional analysis showed that the increase in p-ERK1/2 IR in the nucleus
accumbens shell was the result of a concomitant 5-fold increase (F (2, 15) =61, p < 0.0001) in
the number of p-ERK1/2 positive cells / mm2: mean±SEM cells: Ext – (53.25 ±11.48); saline
– (281.5±29.86); MPEP 10 mg/kg – (10.40±4.776) indicating a cellular pattern of ERK1/2
activation. No significant (F (2, 15) = 0.84, p = 0.4, ns) changes were observed in total
ERK1/2 IR (Table 1) or p-ERK5 IR (Table 2), suggesting that the observed changes were
specific to ERK1/2 phosphorylation and not related to altered abundance of the kinase or general
activation of mitogen activated protein kinase (MAPK) pathways. Representative
photomicrographs illustrating the cytological pattern of p-ERK1/2 IR in the nucleus accumbens
shell following extinction and MPEP (0 or 10 mg/kg) are shown in Figure 2C.
In the nucleus accumbens core, there was an overall trend toward a significant change in p-
ERK1/2 IR associated with cue-induced reinstatement but it failed to reach statistical
significance (F (2, 16) = 3.5, p = 0.054). Pixel density values (mean±SEM: extinction – 1310
±117.7; saline – 1801±207.8; MPEP 10 mg/kg – 1224±151.8) suggested that p-ERK1/2 IR
following the saline-reinstatement condition may have been greater than following extinction
but a planned comparison (t-test) between these two conditions also failed to reach statistical
significance (t (11) = 1.9, p = 0.07), which further confirms the lack of significant change in
p-ERK1/2 IR in the nucleus accumbens core. There was also no change in total-ERK1/2 IR
(Table 1) or p-ERK5 IR (Table 2) in the nucleus accumbens core.
Amygdala (basolateral and central)—In the basolateral amygdala, cue-induced
reinstatement of alcohol-seeking behavior was associated with a significant change in p-
ERK1/2 IR (F (2, 15)=26.4, p < 0.0001). Multiple comparison procedures indicated that the
overall significant difference was due to a 3-fold increase in p-ERK1/2 IR following the saline-
reinstatement condition as compared to extinction (Tukey, p<0.05; Figure 3A). Administration
of MPEP (10 mg/kg) prior to the reinstatement test session completely blocked the increase in
p-ERK1/2 IR that followed saline administration (Tukey, p<0.05; Figure 3A). Cell count
analysis showed that the increase in p-ERK1/2 IR in the basolateral amygdala was associated
with a 59% increase (F (2, 15) = 7.2, p = 0.006) in the number of p-ERK1/2 positive cells /
mm2: mean±SEM cells: Ext – (153±42); saline – (244±36); MPEP 10 mg/kg – (49±18.7) that
the increase in immunoreactivity was partially influenced by an increase in the number of p-
ERK1/2 positive cells. No changes were observed in total-ERK1/2 (Table 1) or p-ERK5 IR
(Table 2) indicating that observed changes in ERK1/2 phosphorylation were not related to an
overall change in kinase abundance or nonspecific activation of MAPK pathways. Figure 3C
shows representative photomicrographs of the basolateral amygdala illustrate the cytological
pattern of p-ERK1/2 IR under extinction and reinstatement conditions.
By contrast, cue-induced reinstatement of alcohol-seeking behavior was not associated with
changes in p-ERK1/2 IR in the central amygdala (i.e., saline-reinstatement not different from
extinction). However, one-way ANOVA identified an overall significant F (2,15) = 3.9, p =
0.04) change in p-ERK1/2 IR, which was due primarily to a significant reduction following
MPEP (10 mg/kg) during reinstatement as compared to extinction (Tukey, p < 0.05; mean
Schroeder et al. Page 7













±SEM pixel density values: extinction – 3343±570; saline – 2522±513 ; MPEP 10 mg/kg –
1555±118). This MPEP-induced inhibition of p-ERK1/2 IR was associated with a trend toward
a reduction in p-ERK1/2 positive cells (data not shown). No changes were observed in total
ERK1/2 IR in the central amygdala (Table 1) indicating that the effects of MPEP (10 mg/kg)
were associated with a specific change in ERK1/2 phosphorylation and not abundance of the
kinase. There was also no change in p-ERK5 IR in the central amygdala (Table 2).
DISCUSSION
The results of this study show that the mGluR5 antagonist MPEP blocks relapse-like behavior
and an associated upregulation of ERK1/2 activation. Using a rat genetic model of alcoholism,
we found that reinstatement of alcohol-seeking behavior, produced by response contingent
presentation of alcohol-associated cues, is associated with a profound 3 – 5 fold increase in
ERK1/2 phosphorylation specifically in the nucleus accumbens shell and basolateral nucleus
of the amygdala. This upregulation of ERK1/2 phosphorylation was solely attributable to cue
exposure and the subsequent alcohol-seeking behavior since no alcohol was presented on the
test day. Both the increase in ERK1/2 phosphorylation and relapse-like behavior was
completely blocked by the mGluR5 antagonist MPEP. We found no changes in total ERK1/2
or in ERK5 phosphorylation, suggesting some degree of specificity for ERK1/2 activation in
cue-induced reinstatement. These findings indicate that cue-induced relapse to alcohol-seeking
behavior is associated with an upregulation of ERK1/2 phosphorylation (i.e., activation)
specifically in sub-nuclei of the amygdala-ventral striatal pathway.
Several recent studies have shown that alcohol exposure alters ERK1/2 phosphorylation.
Moderate doses of acute alcohol (1.5 – 3.5 g/kg) produce a dose- and time-dependent decrease
in p-ERK1/2 in mouse cortex (Kalluri and Ticku, 2002a). Similarly, another recent study
extended these findings by showing that acute ethanol (3.5 g/kg) reduced p-ERK1/2 in the
cerebral cortex and hippocampus in rat pups ranging from PND 5 to adulthood (Chandler and
Sutton, 2005). Evidence also indicates that the ERK/MAPK system may regulate adaptive
changes associated with chronic ethanol exposure and abstinence (Pandey et al., 2008). Forced
exposure to chronic ethanol vapor (blood alcohol levels of approximately 200 mg%)
suppressed p-ERK1/2 immunoreactivity in the amygdala, cortex, cerebellum, and dorsal
striatum in rats (Sanna et al., 2002). Conversely, the same study showed that withdrawal from
ethanol vapor resulted in a time-dependent increase in p-ERK1/2 levels that peaked at 13-h post
withdrawal and remained elevated at 24-h (Sanna et al., 2002). Our results show that response-
contingent exposure to stimuli (i.e., cues) that were previously paired with moderate levels of
self-administered alcohol is sufficient to induce a 5-fold increase in ERK1/2 phosphorylation
specifically in the nucleus accumbens shell and a 3-fold increase in the basolateral amygdala
in alcohol preferring P-rats, and a 3-fold increase in alcohol-seeking behavior. These data in
alcohol preferring P-rats confirm and extend prior results showing that non-contingent
exposure to alcohol paired stimuli increases p-ERK1/2 IR in the lateral amygdala of Wistar rats
(Radwanska et al., 2008). Together, these studies demonstrate that alcohol exposure,
withdrawal, and cue-induced reinstatement are associated with adaptive changes in ERK1/2
activation in the mammalian brain.
In the present study, we also found that systemic administration of the mGluR5 antagonist
MPEP completely blocked cue-induced increases in both ERK1/2 phosphorylation and alcohol-
seeking behavior, which raises the hypothesis that an mGluR5-ERK1/2 pathway may regulate
relapse to alcohol-seeking behavior. This interpretation is consistent with evidence showing
that presentation of cues previously paired with ethanol injection can induce glutamate release
(De Witte, 2004) and that activation of Group I metabotropic glutamate receptors (mGluR1
and 5) increases ERK1/2 phosphorylation in striatal neurons in vivo (Choe and Wang, 2001).
Thus, we propose that exposure to alcohol-associated cues may upregulate ERK1/2
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phosphorylation via increased glutamate activity at mGluR5 receptors in the nucleus
accumbens shell and basolateral amygdala, which in turn mediates relapse-like behavior.
However, increases in ERK1/2 phosphorylation are modulated by activity of a variety of cell
surface proteins, including NMDA receptors (Valjent et al., 2000), which are coupled to
mGluR5 and also regulate relapse-like behavior (Backstrom and Hyytia, 2006). For this reason,
it remains to be determined whether mGluR5 blockade inhibited cue-induced reinstatement of
alcohol-seeking behavior via ERK1/2 inhibition or whether the two effects of the mGluR5
antagonist were independent processes. Functional involvement of ERK1/2 activity in specific
brain regions can be evaluated using a variety of approaches such as microinjection of a specific
MEK/ERK1/2 inhibitor in specific brain regions, which has been shown to inhibit reinstatement
of cocaine-seeking behavior (Lu et al., 2005).
The results of this study complement and extend a growing body of preclinical studies showing
functional regulation of ethanol self-administration and relapse by metabotropic glutamate
receptor activity. For instance, the mGluR5 antagonist MPEP reduces maintenance of operant
alcohol self-administration as well as abstinence- and cue-induced relapse in rats (Backstrom
et al., 2004; Schroeder et al., 2005) in the dose range of 2.5–10 mg/kg which has no effect on
exploratory locomotor behavior in rodents (Henry et al., 2002; Tatarczynska et al., 2001). Other
studies have shown that MPEP, or the more recently available mGluR5 antagonist MTEP,
reduce alcohol self-administration in mice and rats under a variety of experimental conditions
(Besheer et al., 2008; Cowen et al., 2005; Cowen et al., 2007; Hodge et al., 2006), which
demonstrates interspecies generality and further supports specific involvement of mGluR5. In
addition, agonism of presynaptic mGluR2/3 attenuates the ability of formerly drug-paired cues
to reinstate responding (Zhao et al., 2006). Thus, it appears that inhibition of glutamate activity
by blockade of postsynaptic mGluR5, or activation of presynaptic mGluR2/3, is sufficient to
reduce alcohol self-administration and relapse-like behavior. It will be of interest to determine
if reduced ERK1/2 activation is a common downstream mechanism by which mGluR5
antagonists or mGluR2/3 agonists prevent cue-induced reinstatement of alcohol-seeking
behavior via inhibition of glutamate transmission
The results of this study are also consistent with numerous other studies implicating the
basolateral amygdala and nucleus accumbens shell in relapse-like behavior. For example,
evidence suggests that the basolateral nucleus of the amygdala regulates cue-induced
reinstatement of cocaine- and food-seeking behavior (i.e., (Fuchs et al., 2006; Ghitza et al.,
2003; Ledford et al., 2003; McLaughlin and Floresco, 2007; See et al., 2003). Functional
inactivation of the BLA by excitotoxic lesions (Meil and See, 1997), microinjection of
tetrodotoxin (Grimm and See, 2000) or lidocaine (Kantak et al., 2002) have all been shown to
inhibit reinstatement of cocaine-seeking behavior following extinction (reviewed by (Everitt
and Wolf, 2002). Other evidence indicates that activation of dopamine (Schmidt et al., 2006;
Schmidt and Pierce, 2006) or Group II mGluRs (Bossert et al., 2006) in the nucleus accumbens
shell regulates reinstatement of cocaine and heroin seeking-behavior. Overall, the results from
these and numerous other studies suggest that the nucleus accumbens shell and basolateral
amygdala are part of a mesocorticolimbic neural circuit that regulates cue-induced
reinstatement of alcohol, drug, and food-seeking behavior after extinction.
Regulation of cue-induced reinstatement of alcohol-seeking behavior by an mGluR5 –
ERK1/2 pathway in the basolateral amygdala and nucleus accumbens shell is consistent with
the more general role of these proteins and brain regions in learning and memory. Considerable
evidence indicates that the basolateral amygdala modulates memory consolidation in a number
of tasks (Fuchs et al., 2006; Hatfield and McGaugh, 1999; Hsu et al., 2002; Lalumiere et al.,
2004; Miranda et al., 2003; Schroeder and Packard, 2002, 2003, 2004) and growing evidence
implicates ERK/MAPK and mGluR5 in these effects. For example, ERK1/2 is activated (i.e.,
phosphorylated) specifically in the lateral amygdala 60 min after Pavlovian fear conditioning
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in a manner that is dependent on tone-shock pairings, and site-specific infusion of the MEK/
ERK inhibitor U0126 in the lateral amygdala impaired both long-term memory of Pavlovian
fear conditioning and long-term potentiation in the lateral amygdala. This suggests that
activation of the ERK/MAPK pathway is required for memory consolidation and synaptic
plasticity in the amygdala (Schafe et al., 2000). Similarly, infusion of the mGluR5 antagonist
MPEP in the amygdala blocks acquisition of contextual fear conditioning and long-term
potentiation at thalamic input synapses to the lateral amygdala (Rodrigues et al., 2002).
Moreover, the BLA has a direct glutamatergic projection to the nucleus accumbens (Kelley et
al., 1982; Robinson and Beart, 1988) and evidence indicates that the basolateral amygdala and
nucleus accumbens shell (but not the core) interactively modulate memory consolidation
(LaLumiere et al., 2005). Thus, it is plausible that increased ERK1/2 phosphorylation in the
basolateral amygdala and nucleus accumbens shell in the present study may reflect activation
of a memory circuit that processes information about stimuli that are paired with alcohol during
voluntary self-administration. Together, these results underscore the many conceptual and
mechanistic overlaps between the neurobiology of addiction and memory (Kelley, 2004).
Although the present data raise the possibility that that the mGluR5 antagonist MPEP blocked
cue-induced reinstatement of alcohol-seeking by inhibiting the associated increase in
ERK1/2 phosphorylation, a number of potential alternative explanations and limitations to this
study should be discussed. First, an alternative to the interpretation that MPEP specifically
reduced cue-induced reinstatement is that injection of the mGluR5 antagonist may have
reduced general locomotor activity. However, evidence indicates that the highest dose of MPEP
(10 mg/kg) tested in the present study has no effect on exploratory locomotor behavior in P-
rats with a history of alcohol self-administration (Besheer et al., 2008). Second, MPEP may
have reduced cue-induced reinstatement by producing a negative affective state in the subjects.
This possibility also appears unlikely as previous research indicates that MPEP does not
produce a conditioned place preference or conditioned place aversion (McGeehan and Olive,
2003; Popik and Wrobel, 2002). Moreover, MPEP alone does not produce a subjective (i.e.,
discriminative) stimulus effect that resembles alcohol (Besheer and Hodge, 2005), which
suggests that the compound did not act as an alcohol substitute. Third, a limitation of the present
study is that these results show an association between the behavioral effects of MPEP and the
changes in ERK1/2 activation but do not demonstrate functional involvement of ERK1/2 in
reinstatement. Studies that directly manipulate ERK1/2 activation either systemically or in
specific brain regions are required to show functional involvement. Fourth, it will be important
in future studies to dissociate the effects of alcohol-seeking from cue presentation on
ERK1/2 activation to rule out any potential interactions between lever press behavior and
subsequent changes in ERK1/2 phosphorylation. This can be addressed by including a cue-only
control or conducting studies examining effects of contextual cues, which may alter ERK1/2
activation. Finally, one of the main goals of this study was to examine cue-induced changes in
ERK1/2 activity after extinction of alcohol-seeking behavior; however, this approach did not
address potential effects of extinction on ERK1/2 activity, which might be expected since
extinction is an active learning process (Schroeder and Packard, 2003).
Similar to ERK1/2, extracellular-signal-regulated kinase 5 (ERK5) is a member of the multigene
MAP kinase family that is activated (i.e., phosphorylated) by MEK5. Although ERK1/2 is
activated by the separate MEK1/2 pathway, these two MAP kinases share a number of structural
and functional properties that suggest common activities. For example, both ERK1/2 and
ERK5 have a Thr–Glu–Tyr activation motif and show 50% homology of the N-terminal
catalytic domain (Nishimoto and Nishida, 2006), are activated by platelet-derived growth
factor (Abe et al., 1996), and are inhibited by the commonly used MEK1/2 inhibitors, PD98059,
U0126, and PD184352 (Kamakura et al., 1999; Mody et al., 2001), which are commonly
thought to specifically inhibit ERK1/2 activation. For these reasons, we also examined
immunoreactivity of the phosphorylated (i.e., active) form of ERK5 (p-ERK5) in the nucleus
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accumbens and amygdala as a measure of ERK1/2 specificity. P-ERK5 IR was detected at high
levels in all subnuclei of the nucleus accumbens and amygdala. However, no changes were
observed in p-ERK5 IR following cue-induced reinstatement of alcohol-seeking behavior or
administration of MPEP. These data indicate that the observed effects on ERK1/2
phosphorylation were not associated with nonspecific activation of MAPK pathways. It
remains to be determined if phosphorylation of other MAPKs, such as JNK or p38, is altered
during relapse-like behavior.
In conclusion, the MAP kinases have been associated with many of the negative health effects
of alcohol including liver disease, pancreatitis, cancer risk, neurotoxicity, and cardiovascular
disease (Aroor and Shukla, 2004). Results of this study show for the first time that ERK1/2 is
activated in specific sub-nuclei of the amygdala-ventral striatal pathway by response-
contingent presentation of alcohol-associated stimuli. Concomitant blockade of the ERK1/2
activation and relapse-like behavior by the mGluR5 antagonist MPEP suggests that cue-
induced reinstatement of alcohol-seeking may be functionally regulated by an mGluR5 –
ERK1/2 pathway. Overall, these results provide further support for the potential utility of
mGluR5 antagonists in the treatment of problems associated with alcoholism such as relapse,
and provide a novel molecular mechanism by which these compounds may change brain and
behavioral function.
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(A) Extinction of alcohol-reinforced lever pressing. Data are plotted as mean (± SEM) total
responses per session on the ethanol and water levers on the last day of baseline (left) and
through the 9 days of extinction training (right). Data represent an average of 5 treatment groups
(N=31) shown in the lower panel. (B) Effect of the mGluR5 antagonist on cue-induced
reinstatement of alcohol-seeking behavior. Data are shown as mean (± SEM) total responses
on day 10 of the procedure. Bars show performance of a group that continued on extinction
training (Ext) as compared to groups that received MPEP (0 – 10 mg/kg) prior to a cue-induced
reinstatement test session. Data represent mean of n=6–7 rats from each drug dose / condition.
* - significantly different from water on the same day; † - significantly different from Ext within
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the same reinforcement condition; ‡ - significantly different from MPEP (0 mg/kg) within the
same reinforcement condition, p < 0.05, Tukey test.
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Figure 2. p-ERK1/2 IR in nucleus accumbens shell
(A) Mean (± S.E.M.) p-ERK1/2 immunoreactivity (pixels/mm2) in the nucleus accumbens shell
following extinction (Ext) or cue-induced reinstatement with MPEP (0 or 10 mg/kg)
pretreatment. (B) Illustration of brain regions analyzed (adapted from Paxinos and Watson,
1998; nucleus accumbens core – AcbC; nucleus accumbens shell – AcbSh). (C) Representative
photomicrographs of the cytological pattern of p-ERK1/2 IR in the nucleus accumbens shell
following Extinction or cue-induced reinstatement with MPEP (0 or 10 mg/kg) pretreatment.
Data represent means of multiple brain sections from n=6 rats per condition. * - indicates
significantly different from Ext; † - significantly different from MPEP (0 mg/kg), p<0.05,
Tukey test.
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Figure 3. p-ERK1/2 IR in basolateral amygdala
(A) Mean (± S.E.M.) p-ERK1/2 IR (pixels/mm2) in the basolateral amygdala following
extinction (Ext) or cue-induced reinstatement with MPEP (0 or 10 mg/kg) pretreatment. (B)
Illustration of brain regions analyzed (adapted from Paxinos and Watson, 1998; basolateral
amygdala - BLA; central nucleus of the amygdala – CeA. (C) Representative
photomicrographs of the cytological pattern of p-ERK1/2 IR in the basolateral amygdala
following Extinction or cue-induced reinstatement with MPEP (0 or 10 mg/kg) pretreatment.
Data represent means of multiple brain sections from n=6 rats per condition. * - indicates
significantly different from Ext; † - significantly different from MPEP (0 mg/kg), p<0.05,
Tukey test.
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Table 1
Measures of total ERK1/2 immunoreactivity in the N. Accumbens and Amygdala.
Brain Region Treatment Total ERK1/2 IR
(pixels / mm2)
Nucleus Accumbens
    Shell Ext 12403 ± 1931
Veh 9247 ± 1342
MPEP (10 mg/kg) 9770 ± 1995
    Core Ext 9867± 991.8
Veh 11823 ± 1488
MPEP (10 mg/kg) 12417 ± 2136
Amygdala
    Basolateral Ext 8679 ± 1456
Veh 7025 ± 829
MPEP (10 mg/kg) 10248 ± 1472
    Central Ext 10650 ± 1238
Veh 10379 ± 488.8
MPEP (10 mg/kg) 7956 ± 905
Abbreviations – Extinction (Ext); Vehicle (Veh)
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Table 2
Measures of p-ERK5 immunoreactivity in the N. Accumbens and Amygdala.





    Shell Ext 18824 ± 3967 1709 ± 249.4
Veh 14675 ± 2488 1591 ± 194.6
MPEP (10 mg/kg) 15869 ± 2490 1622 ± 167.8
    Core Ext 5626 ± 1211 864.2 ± 149.4
Veh 6336 ± 2246 990.0 ± 293.2
MPEP (10 mg/kg) 5902 ± 719.1 958.6 ± 90.10
Amygdala
    Basolateral Ext 6116 ± 1506 741.3 ± 113.9
Veh 3870 ± 699.6 548.4 ± 72.78
MPEP (10 mg/kg) 5471 ± 1695 619.4 ± 135.5
    Central Ext 19226 ± 2360 1749 ± 50.48
Veh 19046 ± 2941 1717 ± 86.25
MPEP (10 mg/kg) 21025 ± 3773 1636 ± 81.66
Abbreviations – Extinction (Ext); Vehicle (Veh)
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